{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loteprednol&page=2",
    "query": {
      "intervention": "Loteprednol",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loteprednol&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T07:49:36.256Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00834171",
      "title": "A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Loteprednol etabonate ophthalmic suspension 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol etabonate (0.5%) and tobramycin (0.3%).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2009-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2011-09-26",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "Maclean, Virginia",
      "locations": [
        {
          "city": "Maclean",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834171"
    },
    {
      "nct_id": "NCT01475643",
      "title": "Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Loteprednol etabonate",
          "type": "DRUG"
        },
        {
          "name": "Prednisolones acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "Up to 11 Years"
      },
      "enrollment_count": 107,
      "start_date": "2013-06",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475643"
    },
    {
      "nct_id": "NCT02819284",
      "title": "Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 909,
      "start_date": "2016-06",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819284"
    },
    {
      "nct_id": "NCT04708821",
      "title": "DEXTENZA Therapy for Treatment of Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bilateral Conjunctivitis (Disorder)"
      ],
      "interventions": [
        {
          "name": "Dexamethasone ophthalmic insert 0.4Mg",
          "type": "DRUG"
        },
        {
          "name": "0.2% loteprednol etabonate ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinical Research Center of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-04-30",
      "completion_date": "2021-09-02",
      "has_results": false,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "Pompano Beach, Florida",
      "locations": [
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708821"
    },
    {
      "nct_id": "NCT02188160",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2014-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 11,
      "location_summary": "Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02188160"
    },
    {
      "nct_id": "NCT00645671",
      "title": "Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Inflammation"
      ],
      "interventions": [
        {
          "name": "0.5% Loteprednol Etabonate Ophthalmic Ointment",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of Loteprednol Etabonate Ophthalmic Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2008-03",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00645671"
    },
    {
      "nct_id": "NCT00705159",
      "title": "Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "loteprednol etabonate and tobramycin",
          "type": "DRUG"
        },
        {
          "name": "loteprednol etabonate",
          "type": "DRUG"
        },
        {
          "name": "Tobramycin",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of Zylet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Week",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Week to 6 Years"
      },
      "enrollment_count": 137,
      "start_date": "2008-06",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "Erie, Pennsylvania",
      "locations": [
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00705159"
    },
    {
      "nct_id": "NCT00817557",
      "title": "Use of Loteprednol for Contact Lens Intolerance and Dryness",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contact Lenses Dryness"
      ],
      "interventions": [
        {
          "name": "Loteprednol",
          "type": "DRUG"
        },
        {
          "name": "Rewetter",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hom, Milton M., OD, FAAO",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2009-01",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2009-01-06",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "Azusa, California",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00817557"
    },
    {
      "nct_id": "NCT07090044",
      "title": "Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vein Occlusion",
        "Macular Degeneration Choroidal Neovascularization",
        "Macular Edema",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Bromfenac Sodium 0.07%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly",
          "type": "DRUG"
        },
        {
          "name": "Propylene Glycol Preservative-free Artificial Tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Research Institute, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2021-08-20",
      "completion_date": "2022-12-08",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07090044"
    },
    {
      "nct_id": "NCT04911361",
      "title": "The DEPOT Study (Dry Eye Prescription Options for Therapy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Research Insight LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-08-10",
      "completion_date": "2021-12-28",
      "has_results": false,
      "last_update_posted_date": "2022-01-03",
      "last_synced_at": "2026-09-24T07:49:36.256Z",
      "location_count": 3,
      "location_summary": "Hemet, California • Laguna Hills, California • St Louis, Missouri",
      "locations": [
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04911361"
    }
  ]
}